Teva CEO Richard Francis on Q1 Earnings, Tariffs, and US Pharma Supply

Teva's Strong Q1 Performance

• 💡 Teva Pharma reported a strong first quarter, with its innovative business showing significant traction, including a 45% increase in its three leading products.
• 📈 The company's US operations are highlighted as a key growth engine, with innovative products like ETO (for dry eye) up 39%, a schizophrenia drug nearly doubling, and a migraine drug up 26%.
• 🌍 Globally, Teva's generics business also grew by 3%, contributing to overall business growth and a clear path to increased profitability.

Mitigating Tariff Impacts

• 🇺🇸 Teva has mitigated the impact of current tariffs, leveraging its eight US manufacturing sites, including the Florida plant where ETO is produced.
• ⚠️ The company emphasizes a different supply chain footprint compared to competitors, with no reliance on China and minimal reliance on India.
• 🎯 Teva is well-positioned to maintain its financial guidance for the year despite potential policy headwinds and duties.

Addressing Potential Pharma Shortages

• 💊 Teva supplies a significant portion of medicines in the US, with one in 14 prescriptions being a Teva script, ensuring a constant supply chain.
• ✅ The company is committed to preventing shortages and has locked production plans and well-laid-out supply chains for the remainder of the year.
• 🗣️ Teva is actively lobbying to educate policymakers on the value and cost-effectiveness of generics within the US healthcare system.

Generics and Pricing in the US

• 💰 Teva highlights that generic prices in the US are among the lowest globally, making them cost-effective treatments.
• 🏭 Some generics are manufactured in the US, while others are produced in Europe and Israel, diversifying their supply chain.
• 🤝 The industry is working to help the administration understand the crucial role generics play and their affordability.